Oncology Research Program (ORP) today announced funding awards for quality improvement initiatives in CML. The NCCN ORP will oversee these projects, with funding provided by Novartis Pharmaceuticals ...

A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do ...

A recently published human clinical study demonstrates that Promentum® Recover, a patent-pending formula from FutureCeuticals ...

One®, a leader in accessible, high-quality intimate wellness, today introduces a new category of cooling relief products within its Wellness Care Collection ? designed to support women through hot ...

Patients with hematologic malignancies have an increased risk for cardiovascular disease (CVD) compared with the general population.